-
Uncategorized2 months ago
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
-
Uncategorized2 months agoSTAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for...
-
Uncategorized2 months agoSTAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs. At the American Association of Cancer Research annual meeting here,...
-
Uncategorized2 months agoSTAT+: Key GOP senators push back on Trump’s plan to cut NIH, reorganize HHS
WASHINGTON — Both Democratic and Republican Senators who oversee federal spending seemed skeptical of proposed cuts to health research and public health in the White House’s...
-
Uncategorized2 months ago
Medicare indefinitely delays pilot plan to cover weight loss drugs
The Centers for Medicare and Medicaid Services has delayed a key pilot program focused on Medicare coverage for obesity medications, after insurance plans indicated they wouldn’t...
-
Uncategorized2 months agoAlzheimer’s Linked to Cancer Mutations in Brain Immune Cells
As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research reported by researchers at Boston Children’s Hospital suggests that the brain’s...
-
Uncategorized2 months ago
RFK Jr. says China is ‘eating our lunch’ in biotech advances
China is “eating our lunch” on new drug approvals and clinical trial starts, HHS Secretary Robert F. Kennedy Jr. told Congress Tuesday, while praising the FDA’s...
-
Uncategorized2 months ago
Tortugas debuts with $106M and brain drugs from Hansoh, Eisai
Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.
-
Uncategorized2 months ago
Merck’s Welireg combo fails in first-line kidney cancer
Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday....
-
Uncategorized2 months agoMerck’s fast-ascending kidney cancer drug hits a setback
Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said. Read More
